Galmed Pharmaceuticals Ltd.
GLMD
$0.52
$0.0511.19%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 10.22% | -13.18% | 3.83% | -16.10% | -15.91% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 35.55% | 4.82% | 12.59% | -10.88% | -16.20% |
| Operating Income | -35.55% | -4.82% | -12.59% | 10.88% | 16.20% |
| Income Before Tax | -37.14% | -37.57% | -48.26% | -15.56% | -8.75% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -37.14% | -37.57% | -48.26% | -15.56% | -8.75% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -37.14% | -37.57% | -48.26% | -15.56% | -8.75% |
| EBIT | -35.55% | -4.82% | -12.59% | 10.88% | 16.20% |
| EBITDA | -36.03% | -5.29% | -13.70% | 11.85% | 16.97% |
| EPS Basic | 70.19% | 84.34% | 78.75% | 81.67% | 82.78% |
| Normalized Basic EPS | 73.68% | 86.70% | 80.25% | 82.54% | 83.87% |
| EPS Diluted | 70.19% | 84.34% | 78.75% | 81.67% | 82.78% |
| Normalized Diluted EPS | 73.68% | 86.70% | 80.25% | 82.54% | 83.87% |
| Average Basic Shares Outstanding | 362.11% | 472.50% | 387.86% | 330.97% | 457.14% |
| Average Diluted Shares Outstanding | 362.11% | 472.50% | 387.86% | 330.97% | 457.14% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |